JP7641967B2 - ヒト化cldn18.2抗体 - Google Patents
ヒト化cldn18.2抗体 Download PDFInfo
- Publication number
- JP7641967B2 JP7641967B2 JP2022534370A JP2022534370A JP7641967B2 JP 7641967 B2 JP7641967 B2 JP 7641967B2 JP 2022534370 A JP2022534370 A JP 2022534370A JP 2022534370 A JP2022534370 A JP 2022534370A JP 7641967 B2 JP7641967 B2 JP 7641967B2
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- antibody
- amino acid
- identity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19214104 | 2019-12-06 | ||
| EP19214104.2 | 2019-12-06 | ||
| PCT/EP2020/084831 WO2021111003A1 (en) | 2019-12-06 | 2020-12-07 | Humanized cldn18.2 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023505318A JP2023505318A (ja) | 2023-02-08 |
| JP2023505318A5 JP2023505318A5 (cg-RX-API-DMAC7.html) | 2023-10-24 |
| JP7641967B2 true JP7641967B2 (ja) | 2025-03-07 |
Family
ID=68808161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022534370A Active JP7641967B2 (ja) | 2019-12-06 | 2020-12-07 | ヒト化cldn18.2抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12624100B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4069738A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7641967B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220111308A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114901696B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020398045A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3159465A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021111003A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230124037A (ko) * | 2020-12-23 | 2023-08-24 | 소티오 바이오테크 에이.에스. | 종양 특이적 claudin 18.2 항체-약물 접합체 |
| EP4305067A1 (en) | 2021-03-09 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
| EP4349371A4 (en) | 2021-06-02 | 2025-06-25 | Bio-Thera Solutions, Ltd. | DRUG CONJUGATE AND USE THEREOF |
| JP7901102B2 (ja) * | 2021-06-15 | 2026-08-05 | ゼンコア インコーポレイテッド | クローディン18.2及びcd3に結合するヘテロ二量体抗体 |
| US20240350589A1 (en) | 2021-08-13 | 2024-10-24 | Cytune Pharma | Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025078686A1 (en) | 2023-10-12 | 2025-04-17 | Sotio Biotech A.S. | Combination therapy involving antibody-drug conjugates against claudin18.2 and pd1/pd-l axis inhibitors for treatment of cancer |
| WO2025077829A1 (zh) * | 2023-10-13 | 2025-04-17 | 信达细胞制药(苏州)有限公司 | Cldn18.2抗体及car-t细胞在治疗cldn18.2阳性实体瘤中的应用 |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010528075A (ja) | 2007-05-29 | 2010-08-19 | ガニメド ファーマシューティカルズ アーゲー | 癌の治療のためのクローディン18に対するモノクローナル抗体 |
| WO2019173420A1 (en) | 2018-03-08 | 2019-09-12 | Phanes Therapeutics, Inc. | Anti-claudin 18.2 antibodies and uses thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1112364A2 (en) | 1998-09-16 | 2001-07-04 | ZymoGenetics, Inc. | Stomach polypeptide zsig28 |
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| EP1790664A1 (en) * | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| CN105859889B (zh) * | 2010-11-17 | 2020-01-07 | 中外制药株式会社 | 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子 |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| WO2013167153A1 (en) * | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| WO2013174404A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| IL282953B2 (en) | 2012-11-13 | 2026-02-01 | Tron Translationale Onkologie An Der Johannes Gutenberg Univ Mainz Gemeinnutzige Gmbh | Agents for the treatment of claudin-expressing cancers |
| WO2014127785A1 (en) | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014145444A1 (en) * | 2013-03-15 | 2014-09-18 | Pilltek Llc | Systems, methods, and apparatuses for securely dispensing one or more prescribed substances to a securely identified intended user |
| WO2014146672A1 (en) * | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2016165762A1 (en) | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
| WO2018006882A1 (zh) | 2016-07-08 | 2018-01-11 | 科济生物医药(上海)有限公司 | 抗密蛋白18a2的抗体及其应用 |
| CN109970857B (zh) * | 2017-12-27 | 2022-09-30 | 信达生物制药(苏州)有限公司 | 抗pd-l1抗体及其用途 |
| WO2019175617A1 (en) | 2018-03-10 | 2019-09-19 | Pratik Sharma | Data redundancy and elimination module |
| CA3087423A1 (en) | 2018-03-14 | 2019-09-19 | Beijing Xuanyi Pharmasciences Co., Ltd. | Anti-claudin 18.2 antibodies |
| CN116178554B (zh) | 2018-05-18 | 2025-09-09 | 礼新医药科技(上海)有限公司 | 抗密蛋白18.2抗体及其用途 |
| CN109762067B (zh) | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
| BR112022012327A2 (pt) * | 2019-12-23 | 2022-10-18 | Sotio Biotech A S | Anticorpos ou fragmentos dos mesmos, ácido nucleico, vetor e célula hospedeira |
| WO2022122709A1 (en) * | 2020-12-07 | 2022-06-16 | Sotio Biotech A.S. | Antibody-drug conjugates based on humanized cldn18.2 antibodies |
| KR20230124037A (ko) * | 2020-12-23 | 2023-08-24 | 소티오 바이오테크 에이.에스. | 종양 특이적 claudin 18.2 항체-약물 접합체 |
| JP2024524891A (ja) * | 2021-06-23 | 2024-07-09 | サイチューン ファーマ | インターロイキン-15に基づく免疫サイトカイン |
| US20240350589A1 (en) * | 2021-08-13 | 2024-10-24 | Cytune Pharma | Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer |
| US12614475B2 (en) * | 2023-09-06 | 2026-04-28 | Ford Global Technologies, Llc | Systems and methods for facilitating touring in a vehicle |
| WO2025078686A1 (en) * | 2023-10-12 | 2025-04-17 | Sotio Biotech A.S. | Combination therapy involving antibody-drug conjugates against claudin18.2 and pd1/pd-l axis inhibitors for treatment of cancer |
-
2020
- 2020-12-07 JP JP2022534370A patent/JP7641967B2/ja active Active
- 2020-12-07 AU AU2020398045A patent/AU2020398045A1/en active Pending
- 2020-12-07 CA CA3159465A patent/CA3159465A1/en active Pending
- 2020-12-07 EP EP20816527.4A patent/EP4069738A1/en active Pending
- 2020-12-07 US US17/782,417 patent/US12624100B2/en active Active
- 2020-12-07 CN CN202080091553.6A patent/CN114901696B/zh active Active
- 2020-12-07 KR KR1020227022671A patent/KR20220111308A/ko active Pending
- 2020-12-07 WO PCT/EP2020/084831 patent/WO2021111003A1/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010528075A (ja) | 2007-05-29 | 2010-08-19 | ガニメド ファーマシューティカルズ アーゲー | 癌の治療のためのクローディン18に対するモノクローナル抗体 |
| WO2019173420A1 (en) | 2018-03-08 | 2019-09-12 | Phanes Therapeutics, Inc. | Anti-claudin 18.2 antibodies and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3159465A1 (en) | 2021-06-10 |
| CN114901696A (zh) | 2022-08-12 |
| EP4069738A1 (en) | 2022-10-12 |
| AU2020398045A1 (en) | 2022-06-09 |
| JP2023505318A (ja) | 2023-02-08 |
| WO2021111003A1 (en) | 2021-06-10 |
| KR20220111308A (ko) | 2022-08-09 |
| US20230030674A1 (en) | 2023-02-02 |
| CN114901696B (zh) | 2025-08-05 |
| US12624100B2 (en) | 2026-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12624100B2 (en) | Humanized CLDN18.2 antibodies | |
| US20240100180A1 (en) | Tumor-specific claudin 18.2 antibody-drug conjugates | |
| CN113480656B (zh) | 抗ror1抗体 | |
| JP7817162B2 (ja) | 腫瘍特異的クローディン18.2抗体 | |
| US20250236682A1 (en) | Antigen-binding protein comprising two fc domains and use thereof | |
| US20250163157A1 (en) | Bispecific antibodies against cd277 and a tumor-antigen | |
| WO2022122709A1 (en) | Antibody-drug conjugates based on humanized cldn18.2 antibodies | |
| WO2023027164A1 (ja) | Ros(活性酸素種)産生増強剤 | |
| KR20250027598A (ko) | Klrb1 결합제 및 이의 사용 방법 | |
| HK40119369A (en) | ANTI-SIRPα ANTIBODY AND APPLICATION THEREOF | |
| EA046743B1 (ru) | Опухолеспецифические антитела против клаудина 18.2 | |
| WO2026093513A1 (en) | Anti-lrrc15 antibodies and uses thereof | |
| KR20260049221A (ko) | 변형된 e형 다중특이성 항체 | |
| HK40076375B (en) | ANTI-SIRPα ANTIBODY AND APPLICATION THEREOF | |
| WO2025117872A1 (en) | Bispecific antibody-like protein and methods of making and using thereof | |
| BR122025029428A2 (pt) | Anticorpo isolado anti-cd19, sequências de polinucleotídeo isolado e de ácido nucleico, vetores, célula hospedeira, método de expressar o anticorpo, conjugado anticorpo-droga, composição farmacêutica, uso do anticorpo, receptor de antígeno quimérico (car), célula t isolada, método para estimular uma resposta imune, e kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220609 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231016 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231016 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240820 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20241115 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20250110 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250117 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250128 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250225 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7641967 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |